Arq Reports Widened Q1 Loss, Halts GAC Production for FY2026 Amid Design Flaws & Debt Covenant Waivers
ARQ sits 61% above its 52-week low of $1.54.
Summary
Arq, Inc. reported a widened net loss in Q1 2026, driven by a critical decision to halt GAC production for the year due to design flaws, alongside securing waivers for debt covenants, signaling significant operational and financial challenges.
Key Events · Earnings and Guidance · ARQ
-
Q1 Net Loss Widens Significantly
Arq, Inc. reported a net loss of $0.842 million for Q1 2026, a substantial increase from a net income of $0.203 million in Q1 2025, resulting in diluted EPS of ($0.02).
-
GAC Production Halted for FY2026 Due to Design Flaws
The company decided in March 2026 to pause Granular Activated Carbon (GAC) production and idle its Corbin Facility for the entire fiscal year 2026, citing design flaws in the GAC facility and thermal oxidizer limitations. An optimization review is underway, and the company plans to transition to a different coal feedstock.
-
Revenue Exceeds Estimates Amid Operational Challenges
Revenue increased by 7% to $29.053 million for Q1 2026, surpassing analyst estimates of $27.78 million, primarily driven by higher sales volumes of AC products to the power-generation market.
-
Debt Covenant Waivers Secured for CTB Loan
Arq, Inc. entered into an amendment to its CTB Loan on March 5, 2026, which waived certain financial covenants for fiscal year 2025 and suspended testing for fiscal year 2026, requiring increased deposits as a condition.
Analysis · ARQ · Industrial Applications And Services
Arq, Inc.'s Q1 2026 results reveal a significant widening of its net loss to $0.842 million, despite a 7% increase in revenue to $29.053 million, which exceeded analyst estimates. The most critical development is the decision to pause Granular Activated Carbon (GAC) production for the entirety of fiscal year 2026 and idle the Corbin Facility due to persistent design flaws and thermal oxidizer limitations at the Red River Plant. This operational setback is a major blow to the company's growth strategy in advanced purification technologies and is compounded by ongoing litigation with the original design firm. Furthermore, the company secured a waiver for certain financial covenants on its CTB Loan for FY2025 and a suspension of testing for FY2026, requiring increased deposits. This indicates underlying financial stress and reliance on lender accommodation, despite management's assertion of sufficient liquidity for the next 12 months. While cash flow from operations improved significantly, the substantial operational challenges and financial covenant issues present a negative outlook for investors.
At the time of this filing, ARQ was trading at $2.48 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $99M. The 52-week trading range was $1.54 to $7.89. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.